(Press-News.org) Twenty years after the hormone leptin was found to regulate metabolism, appetite, and weight through brain cells called neurons, Yale School of Medicine researchers have found that the hormone also acts on other types of cells to control appetite.
Published in the June 1 issue of Nature Neuroscience, the findings could lead to development of treatments for metabolic disorders such as obesity and diabetes.
"Up until now, the scientific community thought that leptin acts exclusively in neurons to modulate behavior and body weight," said senior author Tamas Horvath, the Jean and David W. Wallace Professor of Biomedical Research and chair of comparative medicine at Yale School of Medicine. "This work is now changing that paradigm."
Leptin, a naturally occurring hormone, is known for its hunger-blocking effect on the hypothalamus, a region in the brain. Food intake is influenced by signals that travel from the body to the brain. Leptin is one of the molecules that signal the brain to modulate food intake. It is produced in fat cells and informs the brain of the metabolic state. If animals are missing leptin, or the leptin receptor, they eat too much and become severely obese.
Leptin's effect on metabolism has been found to control the brain's neuronal circuits, but no previous studies have definitively found that leptin could control the behavior of cells other than neurons.
To test the theory, Horvath and his team selectively knocked out leptin receptors in the adult non-neuronal glial cells of mice. The team then recorded the water and food intake, as well as physical activity every five days. They found that animals responded less to feeding reducing effects of leptin but had heightened feeding responses to the hunger hormone ghrelin.
"Glial cells provide the main barrier between the periphery and the brain," said Horvath. "Thus glial cells could be targeted for drugs that treat metabolic disorders, including obesity and diabetes."
INFORMATION:
Other authors on the study include Jae Geun Kim, Shigetomo Suyama, Marco Koch, Sungho Jin, Pilar Argente-Arizon, Jesus Argente, Zhong-Wu Liu,
Marcelo R Zimmer, Jin Kwon Jeong, Klara Szigeti-Buck, Yuanqing Gao, Cristina Garcia-Caceres, Chun-Xia Yi, Natalina Salmaso, Flora M Vaccarino, Julie Chowen, Sabrina Diano, Marcelo O. Dietrich, and Matthias H. Tschöp.
Citation:
Nature Neuroscience doi: 10.1038/nn.3725
Leptin also influences brain cells that control appetite, Yale researchers find
2014-06-01
ELSE PRESS RELEASES FROM THIS DATE:
Mayo Clinic: Ovarian cancer subtypes may predict response to bevacizumab
2014-06-01
CHICAGO — Molecular sequencing could identify ovarian cancer patients who are most likely to benefit from treatment with bevacizumab (Avastin), a Mayo Clinic-led study has found. Results of the research were presented today at the 2014 American Society of Clinical Oncology Annual Meeting.
The addition of bevacizumab to standard therapy extended progression-free survival more for ovarian cancer patients with molecular subtypes labeled as "proliferative" or "mesenchymal" compared to those with subtypes labeled as "immunoreactive" or "differentiated," says Sean Dowdy, M.D., ...
Oncologists: How to talk with your pathologist about cancer molecular testing
2014-06-01
As targeted therapies become more available, increasing opportunity exists to match treatments to the genetics of a specific cancer. But in order to make this match, oncologists have to know these genetics. This requires molecular testing of patient samples. An education session presented today at the American Society for Clinical Oncology (ASCO) Annual Meeting 2014 details the challenges in this process and makes recommendations that oncologists can use to ensure their patients' samples are properly tested, helping to pair patients with the best possible treatments.
"The ...
Chemotherapy following radiation treatment improves progression-free survival
2014-06-01
CHICAGO — A chemotherapy regimen consisting of procarbazine, CCNU, and vincristine (PCV) administered following radiation therapy improved progression-free survival and overall survival in adults with low-grade gliomas, a form of brain cancer, when compared to radiation therapy alone. The findings were part of the results of a Phase III clinical trial presented today at the 2014 American Society of Clinical Oncology Annual Meeting by the study's primary author Jan Buckner, M.D., deputy director, Cancer Practice, at Mayo Clinic Cancer Center.
"On average, patients who ...
New report estimates nearly 19 million cancer survivors in the US by 2024
2014-06-01
ATLANTA – June 1, 2014 – The number of cancer survivors in the United States, currently estimated to be 14.5 million, will grow to almost 19 million by 2024, according to an updated report by the American Cancer Society. The second edition of Cancer Treatment & Survivorship Facts & Figures, 2014-2015 and an accompanying journal article published in CA: A Cancer Journal for Clinicians find that even though cancer incidence rates have been decreasing for ten years, the number of cancer survivors is growing. This is the result of increases in cancer diagnoses driven by the ...
Reducing emissions will be the primary way to fight climate change, UCLA-led study finds
2014-06-01
Forget about positioning giant mirrors in space to reduce the amount of sunlight being trapped in the earth's atmosphere or seeding clouds to reduce the amount of light entering earth's atmosphere. Those approaches to climate engineering aren't likely to be effective or practical in slowing global warming.
A new report by professors from UCLA and five other universities concludes that there's no way around it: We have to cut down the amount of carbon being released into the atmosphere. The interdisciplinary team looked at a range of possible approaches to dissipating ...
ALTTO test of dual HER2 blockade finds single agent remains the gold standard
2014-06-01
CHICAGO — June 1, 2014 — In the largest clinical trial testing the effectiveness of one versus two drugs to treat HER2-positive breast cancer, lapatinib (Tykerb) did not add benefit to the standard trastuzumab (Herceptin) adjuvant therapy, researchers report at the 50th annual meeting of the American Society of Clinical Oncology (ASCO).
MULTIMEDIA ALERT: Video and audio are available for download on the Mayo Clinic News Network.
Results of the phase III clinical trial, ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization study), demonstrated that adding ...
The ethics of knowing where to stop treatment in a sick and elderly patient
2014-06-01
An Emeritus Professor of medical ethics at Imperial College London will deliver a presentation at this year's Euroanaesthesia meeting titled 'Escalating care for the comorbid elderly-where do we stop?". Raanan Gillon, who is President of the UK's Institute of Medical Ethics, will argue that a patient's age should not in itself be considered an ethically relevant criterion for deciding 'where to stop'.
Acknowledging that there is a morally plausible counter-argument – known in the UK as 'the fair innings argument'- according to which scarce life prolonging resources should ...
Study of 55 million people adds further evidence that patients admitted to hospital at weekends have higher mortality
2014-06-01
A systematic review and meta-analysis of hospital data worldwide, presented as this year's Euroanaesthesia meeting in Stockholm, adds further evidence that patients admitted to hospital at weekends have higher mortality than those admitted on weekdays. The study is by Dr Hiroshi Hoshijima, Tohoku University, Sendai, Japan, and colleagues.
The analysis included 72 studies from various world regions, covering 55,053,719 participants. The authors found that weekend admission was associated with increased morality of between 15% and 17% depending on the statistical technique ...
Risk of death highest following surgery in afternoons, at weekends, and in February
2014-06-01
New research presented at this year's Euroanaesthesia show that on weekends, in the afternoons and in February are the times when the risk of death following surgery is the highest. The research is by Dr Felix Kork and Professor Claudia Spies, Charité - University Medicine Berlin, Germany and colleagues.
Hospital mortality is subject to day-night, weekly and seasonal variability. This has been shown for various populations, settings, and in different regions of the world. However, a cyclic influence on hospital mortality has not been shown in patients after surgery. ...
Poor coverage of specific gene sets in exome sequencing gives cause for concern
2014-06-01
With services based on exome sequencing becoming affordable to patients at a reasonable price, the question of the quality of the results provided has become increasingly important. The exome is the DNA sequence of genes that are translated into protein. These protein-coding regions contain most of the currently-known disease-causing genetic mutations. The American College of Medical Genetics and Genomics (ACMG) has recommended the reporting to patients of clinically actionable incidental genetic findings in the course of clinical exome testing. Specifically, mutations ...